Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Winkler

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Blood|August 1, 2009
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trialThorsten Zenz, Sonja Häbe, Tina Denzel, et al.
International Journal of Cancer|October 12, 2005
Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancerStephan Wolf, Daniel Mertens, Armin Pscherer, et al.
Haematologica|December 3, 2009
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemiaDirk Kienle, Axel Benner, Carolin Läufle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Blood|December 1, 2010
DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testingJulia Mohr, Hanne Helfrich, Maxi Fuge, et al.
Blood|October 23, 2008
miR-34a as part of the resistance network in chronic lymphocytic leukemiaThorsten Zenz, Julia Mohr, Eric Eldering, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
TP53 mutation and survival in chronic lymphocytic leukemiaThorsten Zenz, Barbara Eichhorst, Raymonde Busch, et al.
Journal of Neurology|May 1, 2008
Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-upSwen Hesse, Karl Strecker, Dirk Winkler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 4, 2012
Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048Maria G Beconi, Dawn Yates, Kathryn Lyons, et al.
Haematologica|August 18, 2010
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical riskDirk Winkler, Christof Schneider, Manuela Zucknick, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Blood|August 1, 2009
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trialThorsten Zenz, Sonja Häbe, Tina Denzel, et al.
International Journal of Cancer|October 12, 2005
Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancerStephan Wolf, Daniel Mertens, Armin Pscherer, et al.
Haematologica|December 3, 2009
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemiaDirk Kienle, Axel Benner, Carolin Läufle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Blood|December 1, 2010
DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testingJulia Mohr, Hanne Helfrich, Maxi Fuge, et al.
Blood|October 23, 2008
miR-34a as part of the resistance network in chronic lymphocytic leukemiaThorsten Zenz, Julia Mohr, Eric Eldering, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
TP53 mutation and survival in chronic lymphocytic leukemiaThorsten Zenz, Barbara Eichhorst, Raymonde Busch, et al.
Journal of Neurology|May 1, 2008
Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-upSwen Hesse, Karl Strecker, Dirk Winkler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 4, 2012
Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048Maria G Beconi, Dawn Yates, Kathryn Lyons, et al.
Haematologica|August 18, 2010
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical riskDirk Winkler, Christof Schneider, Manuela Zucknick, et al.
Pageof 10